A phase II study (NCT02091960) that evaluated the combination of enzalutamide with trastuzumab, an anti-HER2 antibody, in patients with AR-positive/HER2-positive breast cancer showed that this combination was well tolerated, but that there was no significant benefit from the combination [110]. The gene discussed is ERBB2; the disease is breast carcinoma.